Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by LSV Asset Management

LSV Asset Management increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,531,050 shares of the specialty pharmaceutical company's stock after purchasing an additional 37,108 shares during the quarter. LSV Asset Management owned approximately 4.19% of Jazz Pharmaceuticals worth $311,699,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Pacer Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after purchasing an additional 115,102 shares in the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 26.6% in the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company's stock valued at $57,142,000 after acquiring an additional 97,589 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Jazz Pharmaceuticals by 501.4% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company's stock worth $13,800,000 after acquiring an additional 93,422 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $11,373,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Jazz Pharmaceuticals by 15.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock valued at $75,801,000 after purchasing an additional 83,807 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Activity at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,140 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares of the company's stock, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,023,305 over the last quarter. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ:JAZZ traded up $0.43 on Tuesday, reaching $102.18. The company had a trading volume of 513,357 shares, compared to its average volume of 782,480. The firm has a market capitalization of $6.21 billion, a PE ratio of 14.39, a PEG ratio of 1.04 and a beta of 0.42. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The firm's 50 day simple moving average is $129.28 and its 200-day simple moving average is $122.70.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Piper Sandler reaffirmed an "overweight" rating and set a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Barclays reissued an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, April 10th. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.